[HTML][HTML] Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li, Y Zhao… - … and Alternative Medicine, 2019 - Springer
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

[HTML][HTML] Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong… - BMC …, 2019 - bmccomplementmedtherapies …
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is
characterized by excessive hepatic lipid accumulation. Many studies have suggested that …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li… - BMC …, 2019 - search.proquest.com
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.

K Fang, F Wu, G Chen, H Dong, J Li… - BMC Complementary …, 2019 - europepmc.org
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

[HTML][HTML] Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li… - BMC Complementary …, 2019 - ncbi.nlm.nih.gov
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li, Y Zhao… - BMC Complementary …, 2019 - go.gale.com
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.

K Fang, F Wu, G Chen, H Dong, J Li… - BMC …, 2019 - search.ebscohost.com
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li, Y Zhao… - … and Alternative Medicine, 2019 - infona.pl
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li… - BMC …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and is characterized by excessive hepatic lipid accumulation. Many studies have …

[引用][C] Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells

K Fang, F Wu, G Chen, H Dong, J Li, Y Zhao, L Xu… - 2019